Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    NCT04365374
Previous Study | Return to List | Next Study

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04365374
Recruitment Status : Recruiting
First Posted : April 28, 2020
Last Update Posted : June 5, 2023
Information provided by (Responsible Party):
GT Medical Technologies, Inc.

Brief Summary:
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRS 3-4 weeks following metastatic tumor resection which is the current standard of care.

Condition or disease Intervention/treatment Phase
Brain Metastases Device: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT) Radiation: Stereotactic Radiation Therapy Phase 3

Detailed Description:

GammaTile therapy results in improved clinical outcomes; however the data is a single site experience with a limited number of subjects, only 12 of which were patients with metastatic brain tumors. The primary objective of this randomized, controlled trial is to compare the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRS 3-4 weeks following metastatic tumor resection which is the current standard of care. The data collected in this trial design will allow for a direct comparisons of a variety of outcomes including local control, overall survival, functional status, quality of life, neurocognitive status and safety in the target population. In order to support direct comparisons, subjects will be randomized to the two equally sized arms (1:1) based on the following stratification factors; age (<60 and ≥60), duration of extracranial disease control (≤3 months vs >3 months), number of metastases (one or two to four), histology (lung and radiation resistant), and the maximal diameter of the index lesion (≤3 cm and >3 cm).

An index lesion meeting the criteria of 2.5cm to 5cm in diameter and appropriate for gross total resection (GTR), will be identified and up to three other non-resectable lesions in a patient will be allowed. After resection of the index lesion the surgical bed will be treated with adjunct radiation (either GT or SRS) thereby following the standard of care guideline. (NCCN Guidelines, 2019). Additional unresected metastatic lesions will be treated with with stereotactic radiosurgery alone, which also adhears to standard of care guidelines.(NCCN Guidelines, 2019).

GammaTile is an FDA-cleared means of rapid dose delivery of radiation therapy directly to the tumor bed with predictable dosimetry at the immediate time of re-resection, and a intense but localized radiation treatment may confer a reduced risk for radiation necrosis compared to other therapies. It is typically easly placed with minimal additional operative time and limited staff radiation exposure.

Given these benefits, the rationale for conducting this randomized control comparison study is to generate additional data, to further support the use of this new FDA-cleared method of delivering radiation therapy in the setting of newly diagnosed brain metastases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Actual Study Start Date : April 6, 2021
Estimated Primary Completion Date : December 30, 2025
Estimated Study Completion Date : December 30, 2027

Arm Intervention/treatment
Experimental: Surgical Resection and GammaTile Therapy
Surgical Resection and GammaTile Therapy
Device: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)
GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
Other Name: Carrier Tile Brachytherapy Therapy (CTBT)

Active Comparator: Surgical Resection and Stereotactic Radiation Therapy
Surgical Resection and Stereotactic Radiation Therapy
Radiation: Stereotactic Radiation Therapy
External Beam Radiation Therapy

Primary Outcome Measures :
  1. Surgical bed recurrence-free survival (SB-RFS) from the time of randomization up to 2 years post radiation. [ Time Frame: up to 2 years post-radiation ]
    Surgical bed control is defined as the absence of new nodular contrast enhancement in the index lesion surgical bed.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: up to 3 years ]
    Survival of subjects

  2. Functional Assessment of Cancer Therapy-Brain (FACT-Br) [ Time Frame: up to 9 months ]
    An assessment of quality of life (QOL)

  3. Linear Analog Scale Assessments (LASA) [ Time Frame: up to 9 months ]
    An assessment of quality of life (QOL)

  4. Hopkins Verbal Learning Test (HVLT-R) [ Time Frame: up to 24 months ]
    An assessment of neurocognitive status

  5. Controlled Oral Word Association Test (COWAT) [ Time Frame: up to 24 months ]
    An assessment of neurocognitive status

  6. Trail Making Tests (TMT) Parts A and B [ Time Frame: up to 24 months ]
    An assessment of neurocognitive status

  7. Barthel ADL [ Time Frame: up to 24 months ]
    An assessment of physical functioning status

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged 18 years old and above. Eligibility is restricted to this age group given that the battery of neurocognitive tests utilized in this protocol are not developed or validated for use in a younger population.
  2. One to four newly diagnosed brain metastases, identified on the screening MRI, from an extracranial primary tumor.
  3. One lesion, designated the index lesion, is planned for surgical resection and is to be between 2.5 cm and 5.0 cm on the screening MRI. Index lesions > 2.0 cm but <2.5 cm are also eligible if surgery is deemed clinically necessary and appropriate for an attempted gross total resection by the neurosurgeon.
  4. Non-index lesions must measure < 4.0 cm in maximal extent on the screening MRI brain scan. The unresected lesions will be treated with SRT as outlined in the treatment section of the concept.
  5. All metastases must be located > 5 mm from the optic chiasm and outside the brainstem. Dural based metastasis are eligible.
  6. Previous and/or concurrent treatment with systemic therapies (e.g., chemotherapy, targeted therapeutics, immunotherapy) is permitted and must follow protocol guidelines as follows: Systemic therapy is allowed a minimum of one week from last systemic therapy cycle to surgical resection, and one week after surgical resection to allow a minimum of one week before starting/resuming systemic therapy, depending on the specific systemic agent(s), as recommended by medical/neuro-oncology. Systemic therapy is not allowed 1 day before SRT, the same day as the SRT, or 1 day after the completion of the SRT or longer, depending on the specific systemic agent(s), as recommended by medical/neuro-oncology. Agents that are delivered by implant or depot injections (such as hormonal therapies) are excluded from these restrictions.
  7. KPS score of ≥70.
  8. Stable systemic disease or reasonable systemic treatment options predicting a life expectancy of ≥6 months.
  9. Ability to complete an MRI of the head with contrast
  10. Adequate renal and hepatic function to undergo surgery, in investigators opinion.
  11. For women of childbearing potential only, a negative urine or serum pregnancy test done < 7 days prior to randomization is required. Women must be willing to notify investigator immediately if they become pregnant at any time during the trial period.
  12. Men and women of childbearing potential must be willing to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment.
  13. Subjects must be fluent in English language to allow for completion of neurocognitive tests and completion of QOL questionnaires. Non-English speaking subjects are not permitted to participate given that participation in the real time integrated neurocognitive function tests is mandatory for all patients. The psychometric properties for translated tests are either not known or not as robust.
  14. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedures.

Exclusion Criteria

  1. Age <18 years.
  2. KPS<70
  3. Past radiation or surgical therapy to the index lesion or the newly diagnosed non-index lesion(s) is exclusionary. However, up to a total of 2 prior courses of SRT treatment to previously diagnosed lesions are allowed as long as any treated lesions are were >15mm from the index lesion.
  4. Patients with >4 newly diagnosed metastases on screening MRI
  5. Pregnant patients.
  6. Primary germ cell tumor, small cell carcinoma, or lymphoma.
  7. Leptomeningeal metastasis (LMD). Note: For the purposes of exclusion, LMD is a clinical diagnosis, defined as radiologic or clinical evidence of leptomeningeal involvement with or without positive cerebrospinal fluid (CSF) cytology.
  8. Prior WBRT for brain metastases.
  9. Concomitant therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
  10. Comorbid psychiatric or neurologic disease or injury impacting cognition, in the opinion of the treating physician, that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
  11. Subjects who, in the investigator's opinion, are unable to understand the protocol or to give informed consent, have a history of poor cooperation, noncompliance with medical treatment, or difficulty in returning for follow up care.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04365374

Layout table for location contacts
Contact: Lisa Misell GT Medical Technologies, PhD (833) 662-0044
Contact: Angela Hall GT Medical Technologies, PT

Layout table for location information
United States, Arizona
HonorHealth Research Institute Recruiting
Phoenix, Arizona, United States, 85027
Contact: John Wanebo, MD         
Principal Investigator: John Wanebo, MD         
United States, California
Keck Hospital of Usc Withdrawn
Los Angeles, California, United States, 90033
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Jeremy Rudnick, MD         
United States, Florida
HCA Florida First Coast Neurology- Orange Park Recruiting
Orange Park, Florida, United States, 32073
Contact: Michael Horowitz, MD    904-272-9981      
Principal Investigator: Michael Horowitz, MD         
United States, Georgia
Piedmont Hospital Active, not recruiting
Atlanta, Georgia, United States, 30309
Winship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Kimberly Bojanowski         
United States, Indiana
Indiana University, IU Health Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Mitesh Shah, MD         
United States, Kansas
The UNIVERSITY OF KANSAS Cancer Center Recruiting
Kansas City, Kansas, United States, 66016
Contact: Paul Camarata         
United States, Michigan
Henry Ford Health Recruiting
Detroit, Michigan, United States, 48202
Contact: Raid Faddah, MBBS, CCRP         
Principal Investigator: Adam Robin, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55414
Contact: Clark Chen, MD         
United States, New York
Memorial Sloan Kettering Recruiting
New York, New York, United States, 10065
Contact: Nelson Moss, MD         
United States, North Carolina
Vidant Health Recruiting
Greenville, North Carolina, United States, 27834
Contact: Stuart Lee, MD    252-847-1550      
United States, Ohio
Mayfield Brain and Spine Recruiting
Cincinnati, Ohio, United States, 45209
Contact: Vincent DiNapoli, MD         
United States, Texas
UT Southwestern, Simmons Cancer Center Recruiting
Dallas, Texas, United States, 75235
Contact: Anita Harris   
Principal Investigator: Toral R Patel, MD         
The University of Texas M. D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Jeffrey Weinberg, MD    713-792-2400   
United States, Washington
Virginia Mason Recruiting
Seattle, Washington, United States, 98101
Contact: Jamie Leitzinger    206-287-6278      
Principal Investigator: Huong Pham, MD         
Sponsors and Collaborators
GT Medical Technologies, Inc.
Layout table for investigator information
Principal Investigator: Jeffrey Weinberg, MD MD Anderson Cancer Center, Houston, TX
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GT Medical Technologies, Inc. Identifier: NCT04365374    
Other Study ID Numbers: GTM-102
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: June 5, 2023
Last Verified: June 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by GT Medical Technologies, Inc.:
New Diagnosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Brain Neoplasms
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases